Revisiting the multiple sclerosis functional composite: proceedings from the National Multiple Sclerosis Society (NMSS) Task Force on Clinical Disability Measures
Approval of new drugs slowing Fewer new prescription drugs will get approved in the U.S. this year than the 30 approved in 2011, a ratings agency forecasts, add
Tucson tech: Tucson’s C-Path drug institute looks to boost its future funding Tucson’s Critical Path Institute recently got some good news – and some noteworthy recognition – when the U.S. S
CDISC, C-Path and FDA Collaborate to Develop Data Standards to Streamline Path to New Therapies The Clinical Data Interchange Standards Consortium (CDISC) and the Critical Path Institute (C-Path) announce the signing of a part
April 6, 2012 Challenges and Recommendations Related to Assuring Quality Outcomes Data Collected via Electronic Platforms
April 6, 2012 Implementing New COA Instruments on Alternative Data Collection Modes: The Electronic Implementation Assessment
Using Translatability Assessment to Refine a Patient-Reported Outcome (PRO) Measure During The Development Process
Stakeholders Share Data to Design Better Trials for Neurodegenerative Diseases The Coalition Against Major Diseases is pooling clinical data to build disease and drug models.